Please try another search
For the fiscal year ended 31 December 2021, Pherecydes Pharma SA revenues was not reported. Net loss applicable to common stockholders increased from EUR1.4M to EUR3.2M. Higher net loss reflects Special Income - Capital decrease of 78% to EUR346K (income), Salaries increase of 50% to EUR2M (expense), Social Expenses increase of 54% to EUR893K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -EUR0.24 to -EUR0.54.
Period Ending: | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
---|---|---|---|---|
Total Revenue | 0.428 | 0.428 | 0 | |
Gross Profit | -0.214 | -0.214 | -0.189 | -0.189 |
Operating Income | -2.44 | -1.7 | ||
Net Income | -1.74 | -1.45 |
Period Ending: | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
---|---|---|---|---|
Total Assets | 14.08 | 15.48 | ||
Total Liabilities | 4.09 | 4.54 | ||
Total Equity | 10 | 11.71 |
Period Ending: | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | ||||
Cash From Investing Activities | ||||
Cash From Financing Activities | ||||
Net Change in Cash |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review